Deterioration in Physical Fitness and Changes in Body Composition After Cisplatin-Based Chemotherapy for Metastatic Testicular Cancer.

Cardiorespiratory fitness declined significantly during cisplatin-based chemotherapy for metastatic testicular cancer.

• VO2 peak decreased by 24% from before the start of CBCT to immediately after the last CBCT cycle (P < .001).
• There was a good correlation between reductions in VO2 peak and quality of life during CBCT (r = 0.54, P = .016).
• No correlation was found between reductions in VO2 peak and physical activity levels.
• The reduction in cardiovascular fitness was suggested to be possibly independent of physical activity level.

Muscle strength and muscular endurance declined significantly during cisplatin-based chemotherapy.

• 1RM leg press decreased by 8% from before to immediately after CBCT (P = .004).
• 1RM chest press decreased by 17% from before to immediately after CBCT (P = .001).
• Chest press muscular endurance decreased by 22% from before to immediately after CBCT (P = .005).

Total lean body mass decreased significantly during cisplatin-based chemotherapy.

• Total lean body mass decreased by 2.2 kg from before the start of CBCT to immediately after the last CBCT cycle (P < .001).
• Body composition was assessed using dual-energy X-ray absorptiometry (DXA).
• 28 patients were included, most with low-volume metastatic disease and all within the good prognosis risk group.

Patient-reported outcomes including quality of life, functional scales, fatigue, and mental health deteriorated significantly during cisplatin-based chemotherapy.

• Significant reductions were observed in physical, role, cognitive, and social functioning, as well as global quality of life.
• Significant increases in total and physical fatigue were observed during CBCT.
• Symptoms of depression increased significantly during CBCT.
• Physical activity levels declined significantly from before to immediately after CBCT.

Most physical fitness and patient-reported outcome variables returned to baseline values by 12 weeks after completion of cisplatin-based chemotherapy.

• Twelve weeks after CBCT, all variables had returned to baseline values except for physical activity levels and physical functioning.
• Physical activity levels and physical functioning remained below baseline at the 3-month post-CBCT assessment.
• The study assessed patients at three time points: before CBCT, immediately after the last CBCT cycle, and 3 months after CBCT completion.

The study sample consisted of 28 metastatic testicular cancer patients treated with cisplatin-based chemotherapy.

• Twenty-eight patients were included in the study.
• Most patients had low-volume metastatic disease.
• All patients were within the good prognosis risk group.
• Assessments included VO2 peak, 1RM and muscular endurance in leg and chest press, DXA-based body composition, physical activity levels, functional scales, global QoL, mental health, and fatigue.